Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 29286M105 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Perceptive Advisors LLC
13G/A
|
10.0% |
8/14/2026
Event 6/30/2026
|
||
| Perceptive Advisors LLC | 10.0% | |||
| Joseph Edelman | 10.0% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | |||
| BML Investment Partners, L.P. 13G/A | 10.0% |
5/14/2026
Event 5/12/2026
|
||
|
Invus Global Management, LLC
13G
|
6.3% |
1/27/2026
Event 1/21/2026
|
||
| Invus Public Equities, L.P. | 5.5% | |||
| Invus Public Equities Advisors, LLC | 5.5% | |||
| Invus Global Management, LLC | 5.5% | |||
| Siren, L.L.C. | 5.5% | |||
| Avicenna Life Sci Master Fund LP | 0.8% | |||
| Avicenna Life Sci Master GP LLC | 0.8% | |||
| Ulys, L.L.C. | 0.8% | |||
| Raymond Debbane | 6.3% | |||
|
Acorn Bioventures, L.P.
13G
|
5.0% |
7/22/2026
Event 7/20/2026
|
||
| Acorn Bioventures, L.P. | 2.1% | |||
| Acorn Capital Advisors GP, LLC | 2.1% | |||
| Acorn Bioventures 2, L.P. | 2.9% | |||
| Acorn Capital Advisors GP 2, LLC | 2.9% | |||
| Anders Hove | 5.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (8) | ||||
|
Deep Track Capital, LP
13G
|
6.7% |
11/18/2025
Event 11/11/2025
|
||
| Deep Track Capital, LP | 6.7% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 6.7% | |||
| David Kroin | 6.7% | |||
| Fonds de solidarite des travailleurs et des travailleuses du Quebec 13G/A | 4.5% |
10/21/2024
Event 9/30/2024
|
||
|
Adage Capital Management, L.P.
13G/A
|
3.0% |
2/12/2025
Event 12/31/2024
|
||
| Adage Capital Management, L.P. | 3.0% | |||
| Robert Atchinson | 3.0% | |||
| Phillip Gross | 3.0% | |||
|
Kynam Capital Management, LP
13G/A
|
2.2% |
2/17/2026
Event 12/31/2025
|
||
| Kynam Capital Management, LP | 2.2% | |||
| Kynam Capital Management GP, LLC | 2.2% | |||
| Yue Tang | 2.2% | |||
|
Biotechnology Value Fund L P
13G/A
|
1.8% |
1/29/2025
Event 1/27/2025
|
||
| Biotechnology Value Fund L P | 1.0% | |||
| BVF I GP LLC | 1.0% | |||
| Biotechnology Value Fund II LP | 0.7% | |||
| BVF II GP LLC | 0.7% | |||
| Biotechnology Value Trading Fund OS LP | 0.1% | |||
| BVF Partners OS Ltd. | 0.1% | |||
| BVF GP Holdings LLC | 1.7% | |||
| BVF Partners L P/IL | 1.8% | |||
| BVF Inc/IL | 1.8% | |||
| Lampert Mark N | 1.8% | |||
|
Cormorant Asset Management, LP
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Cormorant Asset Management, LP | 0% | |||
| Bihua Chen | 0% | |||
|
Foresite Capital Fund VI LP
13G/A
|
0% |
2/14/2025
Event 9/30/2024
|
||
| Foresite Capital Fund VI, L.P. | 0% | |||
| Foresite Capital Management VI, LLC | 0% | |||
| James Tananbaum | 0% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
0% |
8/14/2026
Event 6/30/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 0% | |||
| VHCP Co-Investment Holdings III, LLC | 0% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 0% | |||
| VHCP Management III, LLC | 0% | |||
| VHCP Management EG, LLC | 0% | |||
| Nimish Shah | 0% | |||
| Bong Y. Koh | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 5 | 11.5 M | $19.9 M |
| 2026 Q1 | 60 | 55.9 M | $381 M |
| 2025 Q4 | 58 | 58.8 M | $531 M |
| 2025 Q3 | 37 | 40.9 M | $279 M |
| 2025 Q2 | 38 | 40.4 M | $147 M |
| 2025 Q1 | 32 | 40.9 M | $183 M |
| 2024 Q4 | 35 | 41.3 M | $275 M |
| 2024 Q3 | 31 | 34.3 M | $228 M |
| 2024 Q2 | 33 | 33.8 M | $318 M |
| 2024 Q1 | 35 | 31.7 M | $536 M |
| 2023 Q4 | 14 | 14.2 M | $131 M |